The lead author of the Surviving Sepsis Campaign's latest guideline update highlighted the most important changes for hospitalists to know, including recommendations on the use of fluid and vasopressors.
One hospital's nocturnist service teamed up to develop projects, posters, and papers for publication.
An open-label randomized trial at 60 hospitals in four countries found no increase in organ support-free days in patients who received a therapeutic dose of heparin plus a P2Y12 inhibitor versus heparin alone.
A randomized trial in Australia and New Zealand found similar rates of 90-day mortality and new renal replacement therapy whether ICU patients were given a balanced multi-electrolyte solution (Plasma-Lyte 148) or saline.
An analysis of an unsanctioned safe consumption site found that patients who used it were 27% less likely to visit the ED and 32% less likely to be hospitalized than those who did not.
A pragmatic cluster randomized trial at four Australian hospitals found that “Eat Walk Engage” did not reduce length of stay or overall hospital-associated complications compared to usual inpatient care.
Hospitalists have had to find new strategies during the pandemic in order to provide optimal care, including company and comfort, to dying inpatients and their families.
A patient presented with nausea, loss of appetite, and weight loss of approximately 20 pounds. Lab tests revealed hypercalcemia.
The tool used real-time patient data and a trained prediction algorithm to notify the hospitalist if the patient had a high likelihood of nighttime vital sign measurements within reference ranges.
A retrospective cohort study of mostly male veterans found that 10.8% received a new antipsychotic prescription during index hospitalization for heart failure, 21.5% of which were continued after discharge to a skilled nursing facility (SNF).
The NIH updated its guidelines to address anticoagulation in COVID-19 inpatients, treatment with atorvastatin did not appear to improve outcomes in the ICU, and several studies looked at characteristics of omicron.
A double-blind, randomized controlled trial of 124 ICU patients with septic shock found that while 28-day mortality was lower in those who received IV vitamin C versus placebo, the absolute risk reduction did not reach statistical significance.
Learn how the hospital and the home are the same but different.
An electronic newsletter that covers the latest news in internal medicine, delivered directly to your inbox each Tuesday.
An electronic newsletter that focuses on news specific to diabetes, delivered directly to your inbox once per month.
An electronic newsletter that focuses on news specific to gastroenterology and hepatology, delivered directly to your inbox once per month.